Table 3.

Disease activity measured by SLEDAI-2 K score in the SLE patients at time-point of blood sampling

Groups	Patient group I n = 84	Patient group II n = 140
SLEDAI-2 K score, median (min–max)	6 (0–32)	2.0 (0–18)
Seizures (%)	1.2	0
Psychosis (%)	0	0
Organic brain syndrome (%)	0	0.7
Visual disturbance (%)	2.4	0
Cranial nerve disorder (%)	1.2	0
Lupus headache (%)	1.2	2.1
Cerebrovascular accident (CVA) (%)	3.6	0
Vasculitis (%)	2.4	0.7
Arthritis (%)	23.8	10.0
Myositis (%)	2.4	0
Kidney involvement (urinary cast, hematuria, proteinuria, or pyuria) (%)	25.0	10.7
Rash (%)	34.5	11.4
Oral or nasal ulcers (%)	2.4	2.1
Pleurisy (%)	4.8	0.7
Pericarditis (%)	4.8	0
Low complement (C3 or C4) (%)	44.0	25.0
Anti-dsDNA antibodies (%)	28.6	12.1
Fever (%)	10.7	0
Thrombocytopenia (%)	6.0	1.4
Leukopenia (%)	15.5	6.4
Alopecia (%)	9.5	2.1

In patient group I, plasma samples were drawn at time points of higher disease activity to investigate plasma apoM levels in relation to disease activity. In patient group II, plasma samples were drawn in consecutive patients to investigate apoM levels in relation to endothelial function. Individual items in SLEDAI-2 K score are shown

SLEDAI-2 K score was lower in patient group II